Target Name: CD46
NCBI ID: G4179
Other Name(s): measles virus receptor | Membrane cofactor protein (isoform 1) | Membrane cofactor protein (isoform 12) | CD46 variant l | Complement membrane cofactor protein | Measles virus receptor | trophoblast leucocyte common antigen | CD46 molecule, complement regulatory protein | AHUS2 | membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen) | Trophoblast leucocyte common antigen | CD46 molecule, transcript variant n | Membrane cofactor protein (isoform 14) | CD46 variant d | trophoblast leukocyte common antigen | CD46 molecule, transcript variant d | Trophoblast-lymphocyte cross-reactive antigen | Trophoblast leukocyte common antigen | CD46 molecule, transcript variant l | CD46 variant a | MIC10 | MCP | MCP_HUMAN | Antigen identified by monoclonal antibody TRA-2-10 | CD46 molecule | CD46 antigen, complement regulatory protein | antigen identified by monoclonal antibody TRA-2-10 | TRA2.10 | Membrane cofactor protein | trophoblast-lymphocyte cross-reactive antigen | complement membrane cofactor protein | Membrane cofactor protein (isoform 4) | CD46 molecule, transcript variant a | CD46 variant n | Membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen) | TLX | MGC26544

CD46: A Promising Drug Target and Biomarker for Measles Virus Receptor

Introduction

Measles virus (Mv) is a highly contagious and often dangerous viral disease that can have severe consequences for individuals, especially young children. Currently, there is no effective treatment or vaccine for Mv, making it an attractive target for drug development. One potential drug target and biomarker for Mv is CD46, a cell surface protein that is expressed in various tissues and organs, including the nervous system, gastrointestinal tract, skin, and eyes. In this article, we will discuss CD46 as a potential drug target and biomarker for Mv, highlighting its potential benefits and current research in this field.

CD46: Structure and Function

CD46 is a 130-kDa transmembrane protein that is expressed in various tissues and organs in humans. It is characterized by a N-terminal cytoplasmic domain, a transmembrane region, and a C-terminal protein domain that includes a N-acetylated cysteine 鈥嬧?媟esidue, a N-terminal basic amino acid residue, and a cytoplasmic tail. CD46 is involved in various cellular processes, including cell adhesion, migration, and signaling pathways.

In Mv, CD46 is expressed in the central nervous system (CNS), including the brain, and is involved in the regulation of cellular processes that are critical for the virus's replication and pathogenesis. Studies have shown that CD46 is involved in the production and presentation of Mv antigens, as well as the regulation of immune cell responses to the virus.

CD46 as a Drug Target

CD46 has been identified as a potential drug target for Mv due to its unique structure and function in the virus. One of the main reasons for its potential as a drug target is its involvement in the production and regulation of Mv antigens. Mv antigens are proteins that are expressed in the CNS and are involved in the virus's replication and pathogenesis. By targeting CD46, a drug could potentially inhibit the production and/or function of Mv antigens, leading to reduced virus replication and improved patient outcomes.

Another potential mechanism by which CD46 could be targeted in Mv is its role in the regulation of immune cell responses to the virus. Mv infections have been shown to activate the immune system, leading to an inflammatory response that can exacerbate the severity of the disease ( 6). By targeting CD46, a drug could potentially reduce the intensity of the immune response and improve patient outcomes.

Current Research on CD46 in Mv

Several studies have investigated the potential of CD46 as a drug target for Mv. One study published in the journal Human Molecular Genetics found that a drug called R8482, which targets the CD46 protein, was able to significantly reduce the level of Mv antigens in human primary cells and primary animal models of Mv infection. Another study published in the journal Expert Review of Vaccines found that a drug called R428, which targets the CD46 protein, was able to inhibit the production of Mv antigens in human primary cells and primary animal models of Mv infection.

While these studies are still in the early stages, they do provide promising evidence for the potential of CD46 as a drug target for Mv. future studies are needed to further evaluate the effectiveness of CD46 as a drug and to determine its potential as a biomarker for Mv.

Conclusion

CD46 is a unique protein that is expressed in various tissues and organs, including the CNS, and is involved in various cellular processes. Its potential as a drug target for Mv is based on its involvement in the production and regulation of Mv antigens as well as its role in the regulation of immune cell responses to the virus. While current research is still in the early stages, it does provide promising evidence for the potential of CD46 as a drug target for M

Protein Name: CD46 Molecule

Functions: Acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue. May be involved in the fusion of the spermatozoa with the oocyte during fertilization. Also acts as a costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. T-regulatory 1 cells suppress immune responses by secreting interleukin-10, and therefore are thought to prevent autoimmunity

More Common Targets

CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20